KalVista Pharmaceuticals (NASDAQ:KALV) Price Target Cut to $20.00

KalVista Pharmaceuticals (NASDAQ:KALV) had its target price cut by HC Wainwright from $24.00 to $20.00 in a research report sent to investors on Friday morning, Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.

Separately, Needham & Company LLC reiterated a buy rating and issued a $35.00 price objective on shares of KalVista Pharmaceuticals in a report on Wednesday.

KalVista Pharmaceuticals Stock Down 0.3 %

Shares of KalVista Pharmaceuticals stock traded down $0.04 during trading on Friday, hitting $12.13. 199,657 shares of the stock traded hands, compared to its average volume of 353,364. The company has a fifty day moving average price of $12.12 and a two-hundred day moving average price of $11.40. KalVista Pharmaceuticals has a twelve month low of $7.21 and a twelve month high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Monday, March 11th. The specialty pharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.09). On average, equities research analysts expect that KalVista Pharmaceuticals will post -3.05 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Venrock Healthcare Capital Par purchased 4,474 shares of the company’s stock in a transaction dated Tuesday, February 6th. The shares were bought at an average price of $14.74 per share, with a total value of $65,946.76. Following the completion of the transaction, the insider now directly owns 4,743,157 shares in the company, valued at approximately $69,914,134.18. The purchase was disclosed in a filing with the SEC, which is available through this link. In other KalVista Pharmaceuticals news, CFO Benjamin L. Palleiko sold 22,802 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $14.11, for a total transaction of $321,736.22. Following the completion of the sale, the chief financial officer now directly owns 187,315 shares in the company, valued at $2,643,014.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Venrock Healthcare Capital Par acquired 4,474 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was acquired at an average price of $14.74 per share, for a total transaction of $65,946.76. Following the completion of the purchase, the insider now directly owns 4,743,157 shares of the company’s stock, valued at approximately $69,914,134.18. The disclosure for this purchase can be found here. Insiders sold 75,978 shares of company stock valued at $1,070,918 over the last 90 days. 12.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of KalVista Pharmaceuticals by 9.6% in the third quarter. Vanguard Group Inc. now owns 1,732,489 shares of the specialty pharmaceutical company’s stock worth $16,684,000 after acquiring an additional 151,808 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of KalVista Pharmaceuticals by 5.1% during the 4th quarter. SG Americas Securities LLC now owns 137,817 shares of the specialty pharmaceutical company’s stock worth $1,688,000 after purchasing an additional 6,670 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of KalVista Pharmaceuticals during the fourth quarter valued at about $49,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at about $126,000. Finally, New York State Common Retirement Fund grew its holdings in shares of KalVista Pharmaceuticals by 1,860.4% during the 3rd quarter. New York State Common Retirement Fund now owns 9,959 shares of the specialty pharmaceutical company’s stock worth $96,000 after purchasing an additional 9,451 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.